BOUL.ST
Latest Trade
47.50SEKChange
-1.00(-2.06%)Volume
7,288Today's Range
-
49.0552 Week Range
-
74.00As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 48.50 |
|---|---|
Open | 49.05 |
Volume | 7,288 |
3M AVG Volume | 0.82 |
Today's High | 49.05 |
Today's Low | 47.50 |
52 Week High | 74.00 |
52 Week Low | 37.45 |
Shares Out (MIL) | 19.42 |
Market Cap (MIL) | 922.29 |
Forward P/E | 27.38 |
Dividend (Yield %) | 1.16 |
Boule Diagnostics Q2 Operating Profit Down At SEK 5.9 Million
Boule Diagnostics: Fredrik Dalborg Leaves Position As CEO
Boule Diagnostics Q1 Operating Profit Down At SEK 16.7 Million
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Company’s product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Company’s primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
Industry
Medical Equipment & Supplies
Executive Leadership
Peter von Ehrenheim
Independent Chairman of the Board
Fredrik Dalborg
President, Chief Executive Officer
Christina Rubenhag
Chief Financial Officer, Senior Vice President
Fredrik Ekdahl
Senior Vice President Research & Development
Michael Elliott
Senior Vice President Research & Development at CDS
Price To Earnings (TTM) | 43.03 |
|---|---|
Price To Sales (TTM) | 2.03 |
Price To Book (MRQ) | 3.04 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 50.41 |
LT Debt To Equity (MRQ) | 17.35 |
Return on Investment (TTM) | 6.03 |
Return on Equity (TTM) | 4.28 |
* SAID ON FRIDAY UNIT BOULE MEDICAL RECEIVED A WARNING LETTER FROM THE US FOOD AND DRUG ADMINISTRATION
* UNIT BOULE MEDICAL AB BUYS NEW TECHNOLOGIES FROM DREW SCIENTIFIC, INC.
* Q4 NET SALES SEK 107.2 MILLION VERSUS SEK 104.6 MILLION YEAR AGO
* Q3 NET SALES SEK 109.7 MILLION VERSUS SEK 108.5 MILLION YEAR AGO
* CHRISTINA RUBENHAG NEW CFO FROM OCT.9 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Q2 NET SALES SEK 104.3 MILLION VERSUS SEK 102.0 MILLION YEAR AGO
* BOULE DIAGNOSTICS OPTIMIZES MANUFACTURING STRUCTURE - CLOSES FACTORY IN CHINA
* Q1 NET SALES SEK 106.6 MILLION VERSUS SEK 84.4 MILLION YEAR AGO
* Installation of instruments will begin in Q2 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Q4 net sales 105.8 million Swedish crowns ($11.89 million) versus 88.4 million crowns year ago
* Q4 net sales 105.8 million Swedish crowns ($12 million)versus 88.4 million crowns year ago
* Said on Wednesday had revised its financial targets and adjusted dividend policy
Boule Diagnostics AB : * Wins new procurement in India * Systems will be delivered during first quarter of 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Says Tredje AP-fonden buys 358,068 shares in Boule Diagnostics AB corresponding to 7.6 percent stake
* Dalborg to replace Ernst Westman, who will leave CEO post and company in Q1 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* Q3 net sales 108.5 million Swedish crowns ($12 million)versus 88.8 million crowns year ago
* Wins assignment from Red Cross in Kenya Source text for Eikon:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.